Differences in target organ damage between captopril challenge test-defined definitive-positive and borderline-range groups among patients with primary aldosteronism.
Fujiwara N, Haze T, Wakui H, Tamura K, Tsuiki M, Kamemura K, Taura D, Ichijo T, Takahashi Y, Watanabe M, Kobayashi H, Nakamura T, Izawa S, Wada N, Yamada T, Yokota K, Naruse M, Sone M; JPAS II study group.
Fujiwara N, et al. Among authors: yokota k.
Hypertens Res. 2024 Oct 15. doi: 10.1038/s41440-024-01943-w. Online ahead of print.
Hypertens Res. 2024.
PMID: 39402300